Application 761122
- Type
- BLA
- Sponsor
- GLAXOSMITHKLINE
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761122 | Nucala | mepolizumab | 351(a) | Rx | 2026-08-01 |
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | NUCALA | MEPOLIZUMAB | INJECTABLE;SUBCUTANEOUS | 100MG/ML | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Nucala | MEPOLIZUMAB | GlaxoSmithKline LLC | fefb887c-e4ac-431e-8893-e9d1a5a63fea | 2025-08-06 | Warnings, Adverse reactions | BLA761122 0173-0892 0173-0904 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0173-0892 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0892 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0892 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0892 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0892 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0892 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0892 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0892 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0892 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0892 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0904 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
| 0173-0904 | Nucala | mepolizumab | GlaxoSmithKline LLC | BLA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 83128 | SUPPL | 2025-08-19 |
| 83062 | SUPPL | 2025-08-07 |
| 73785 | SUPPL | 2023-03-17 |
| 73775 | SUPPL | 2023-03-16 |
| 69973 | SUPPL | 2022-01-26 |
| 69958 | SUPPL | 2022-01-25 |
| 68266 | SUPPL | 2021-08-02 |
| 68249 | SUPPL | 2021-08-02 |
| 64739 | SUPPL | 2020-09-29 |
| 64673 | SUPPL | 2020-09-25 |
| 60002 | SUPPL | 2019-09-13 |
| 60001 | SUPPL | 2019-09-13 |
| 59994 | SUPPL | 2019-09-13 |
| 59993 | SUPPL | 2019-09-13 |
| 59839 | ORIG | 2019-08-26 |
| 58995 | ORIG | 2019-06-07 |
| 58987 | ORIG | 2019-06-07 |
| 66960 | ORIG | 1900-01-01 |
| 63141 | ORIG | 1900-01-01 |